Boston Scientific Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael F. Mahoney
- Full Time Employees
- 59,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 300 Boston Scientific Way Marlborough MA United States 01752-1234
- IPO Date
- May 19, 1992
- CIK
- 0000885725
- Website
- bostonscientific.com
- Similar Companies
- Business
- Boston Scientific Corporation (NYSE: BSX) develops, manufactures and markets innovative medical devices for a wide range of interventional medical specialties worldwide. The company operates through two primary reportable segments, MedSurg and Cardiovascular, encompassing eight core businesses: Cardiac Rhythm Management, Electrophysiology, Endoscopy, Interventional Cardiology Therapies, Neuromodulation, Peripheral Interventions, Urology and WATCHMAN; its product portfolio includes pacemakers, defibrillators (S-ICD, ICD), CRT-P devices, deep brain stimulation systems, radiofrequency ablation systems for pain management, renal denervation technologies, direct visualization systems, embolic protection and embolization devices, FFR and IVUS systems, guidewires, imaging systems, intragastric balloons, lasers for BPH and lithotripsy, plaque modification tools, retrieval devices, RF ablation systems, hemostasis needles, hepatopancreatobiliary stents, hydrogel spacers, infection prevention products, pelvic floor reconstruction devices, penile prostheses and single-use imaging systems. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company maintains commercial operations in over 127 countries, including the U.S., Europe, Middle East and Africa, Asia-Pacific, Latin America and Canada, serving approximately 44 million patients annually through healthcare professionals in fields such as interventional cardiology, endoscopy, neuromodulation, peripheral interventions and urology. In recent developments, Boston Scientific has pursued an aggressive acquisition strategy, including agreements to acquire Bolt Medical for up to $664 million to enhance its intravascular lithotripsy offerings for coronary and peripheral artery disease (expected close in first half of 2025), SoniVie Ltd. for up to $600 million to advance therapeutic intravascular ultrasound for renal denervation in hypertension treatment (expected close in first half of 2025), Elutia's BioEnvelope division to reduce complications in cardiac rhythm management devices, Anrei Medical for $182 million to bolster endoscopy solutions, Intera Oncology for interventional oncology in liver metastases, and Cortex; the company also completed its $3.7 billion acquisition of Axonics in November 2024 and received $2.6 million in state funding for a 52,000-square-foot manufacturing expansion at its Maple Grove, Minnesota campus to support WATCHMAN product growth, alongside launching approximately 100 new products in 2024.
Company News
Boston Scientific Corporation $BSX Stock Bought by Ethic Inc.
BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation's Directors and Officers for Breach of Fiduciary Duties – BSX
Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock
BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays Weak
Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?
Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.
New Strong Sell Stocks for October 30th
Penumbra, Inc. Reports Third Quarter 2026 Financial Results
BSX Q3 Earnings Call Flags Growth Challenges Through 2027
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Boston Scientific, eBay, Fervo Energy, Fortinet, Hilton Worldwide Holdings, Lennox International, Palantir Technologies, and More
These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results
Boston Scientific Q3 Earnings Call Highlights
Boston Scientific: 3 Key Takeaways for Long-Term Investors
Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact
BSX Q3 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
Boston Scientific Corporation (BSX) Q3 2026 Earnings Call Transcript
Compared to Estimates, Boston Scientific (BSX) Q3 Earnings: A Look at Key Metrics